Pendapatan reged perusahaan Qualigen Therapeutics, Inc. (QLGN)

Developing drugs for cancer and viruses involves colossal risks and a fierce struggle against industry behemoths. A severe capital shortage jeopardizes operational activities, necessitating an urgent search for investments. Qualigen Therapeutics (QLGN) bases its revenues on FastPack diagnostic systems and nanotechnologies, while the company's sales history demonstrates that the figure has stalled at 0.00.

For a fundamental valuation of Qualigen Therapeutics (QLGN), it is critical to understand its status as a pre-revenue biotech focused on clinical trials. This indicator tracks daily cash inflows from product sales; however, the company's current revenue trend reflects a total absence of market sales and a complete business reliance on equity offerings to fund operating expenses.